BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

19 Apr 2024 11:04:56 By NetDania Notify

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

17 Apr 2024 04:30:39 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

05 Apr 2024 09:45:07 By NetDania Notify

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

04 Apr 2024 15:51:53 By NetDania Notify

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

03 Apr 2024 09:45:12 By NetDania Notify

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Apr 2024 07:00:23 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

02 Apr 2024 12:00:22 By NetDania Notify

BioCryst to Present at Upcoming Investor Conferences

25 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

14 Mar 2024 13:48:51 By NetDania Notify

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Mar 2024 07:01:47 By Nasdaq GlobeNewswire

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

26 Feb 2024 07:00:05 By Nasdaq GlobeNewswire

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

23 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

21 Feb 2024 16:01:58 By Nasdaq GlobeNewswire

BioCryst Launches ORLADEYO® (berotralstat) in Italy

19 Feb 2024 07:54:52 By Nasdaq GlobeNewswire

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

12 Feb 2024 07:00:53 By Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

05 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 07:00:48 By Nasdaq GlobeNewswire

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

05 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2024 16:01:59 By Nasdaq GlobeNewswire

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 07:00:50 By Nasdaq GlobeNewswire